UNIMARK REMEDIES LIMITED

Public Limited Indian Non-Government CompanyUnlistedACTIVE compliantCIN: U23200MH1993PLC075373

INDICATIVE PRICE₹123Last updated 9 Apr 2026

Ask AI

UA Score75/100

CIN

🔒

CIN

Incorp. Date01 Dec 1993

Paid-up Capital₹10.00 Cr

Open Charges₹1064.65 Cr

Last AGM29 Dec 2025

PAN

🔒

PAN

Company Summary

Unimark Remedies Limited (URL), a Public Limited Indian Non-Government Company, was incorporated on December 1, 1993, in Maharashtra. Operating within the pharmaceutical industry, URL focuses on the m…

PharmaAPI Manufacturers

Incorporation01 Dec 1993

Age33+ years

PANAAACU0589R

StatusUnlisted

LocationMumbai, Maharashtra

IndustryPharma

🎙️ Company Audio Brief

1-Minute Company Overview

Listen to key insights • 1:00 min

💡 Quick Investor Summary

🏢

What They Do

Unimark Remedies Limited (URL), a Public Limited Indian Non-Government Company, was incorporated on December 1, 1993, in Maharashtra. Operating within...

📈

Financial Health

Reporting Between 50 and 250 cr. in revenue. Currently operating at a loss making.

🛡️

Positive Aspects

Maintains active compliance with regulators.

⚠️

Key Risk

Payment delays in EPF (true). Significant registered debt charges open.

Key Highlights

ℹRevenue: Between 50 and 250 cr.

⚠Profit: Loss Making

⚠Bureau defaults on record

⚠Pending legal cases filed

⚠GST filing delay: true

⚠EPF payment delay: true

ℹEmployees: Upto 100

Management Team

JITESH RAMESHCHANDRA KHOKHANI

DirectorDIN: 00611815Since 26 May 2023

KETAN BHUPENDRABHAI PARIKH

Additional DirectorDIN: 07787288Since 27 May 2023

SONALIKA SUSHANT SHRIVASTAV

Additional DirectorDIN: 09209953Since 06 Sept 2024

more directors

Show 29 past directors

VIJAY INDRAVADAN DAVE

DirectorDIN: 00401236Ceased 31 Mar 2008

YOGESH PARIKH NAVNITLAL

Whole-time directorDIN: 00048121Ceased 02 Jan 2017

MEHUL JAYANT PAREKH

Managing DirectorDIN: 00026776Ceased 26 May 2023

PERUMAL SRINIVASAN

Additional DirectorDIN: 00365025Ceased 29 Jul 2009

CHAITANYA CHHOTUBHAI DESAI

Whole-time directorDIN: 02775892Ceased 06 Nov 2010

SONALI MEHUL PAREKH

DirectorDIN: 06689437Ceased 26 May 2023

SRINIVAS KOPPISETTY

DirectorDIN: 00514607Ceased 27 Jun 2017

SANJEEV ANANT GUPTE

DirectorDIN: 03042650Ceased 13 Feb 2014

HIMADRI SEN

Whole-time directorDIN: 03552235Ceased 15 Apr 2013

VINAYAK PRABHAKAR SHENVI

Director appointed in casual vacancyDIN: 00694217Ceased 17 Jun 2011

RANCHODLAL KESHAVLAL SHAH

DirectorDIN: 03470002Ceased 05 Feb 2018

OM TYAGI

Whole-time directorDIN: 01965135Ceased 17 Oct 2016

VIJAY KUMAR BATRA

Additional DirectorDIN: 00038275Ceased 19 Dec 2013

TARUN PARESHCHANDRA GUPTA

Additional DirectorDIN: 02667140Ceased 25 Jul 2012

SANDIP JAYANT PAREKH

DirectorDIN: 00048033Ceased 26 May 2023

HARMANDER PAL SINGH CHAWLA

DirectorDIN: 00015627Ceased 05 Feb 2018

RAJIV SARMAN SHUKLA

DirectorDIN: 02143904Ceased 31 May 2013

SHEKHAR RAMCHANDRA SHANBHAG

DirectorDIN: 03518366Ceased 07 Mar 2014

JOHN WILLIAM SCOTT

DirectorDIN: 02091684Ceased 05 Apr 2012

RAMESH NARSIBHAI PATEL

DirectorDIN: 02656834Ceased 10 Jun 2013

FADI KHADER SALIM NASSAR

DirectorDIN: 06845579Ceased 24 Mar 2016

YOGESH PARIKH NAVNITLAL

CFOCeased 26 May 2023

RAHUL DUBEY

Company SecretaryCeased 28 Apr 2014

OMPRAKASH SINGH

Company SecretaryCeased 17 Apr 2011

SUNIL GOPALAN NAIR

Company SecretaryCeased 01 Mar 2008

MOHAMMAD ABDUL NADEEM

Company SecretaryCeased 08 Mar 2013

ABDUL LATIF

Company SecretaryCeased 30 Nov 2018

ANANDGHAN BOHRA

Company SecretaryCeased 30 Aug 2014

ALPA GIRISH MEHTA

Company SecretaryCeased 17 Jun 2011

🔒

IPO Tracker

📊 Showing 1 year of data. Upgrade to Premium for full 5-year history.

Total Employees

Upto 100

CSR Expenditure

Not Specified

Positive Signal: Strong Operating Cash Flow (₹1,22,97,43,890) despite reporting net losses. Core operations are generating cash.

Profit & Loss Statement

Line Item	FY 2019
Net Revenue	₹103.71 Cr
Total Operating Cost	₹41.52 Cr
Operating Profit / (Loss)	-₹42.71 Cr
Other Income	₹40.84 L
Depreciation	₹31.81 Cr
Profit Before Tax	-₹197.72 Cr
Income Tax	₹0
Profit After Tax (PAT)	-₹197.72 Cr

Balance Sheet

Line Item	FY 2019
ASSETS
Non-Current Investments	₹2.75 L
Net Fixed Assets	₹307.03 Cr
Total Non-Current Assets	₹31.18 Cr
Cash & Bank Balances	₹2.57 Cr
Trade Receivables	₹14.70 Cr
Total Current Assets	₹44.33 Cr
Total Assets	₹574.73 Cr
LIABILITIES & EQUITY
Share Capital	₹34.47 Cr
Reserves & Surplus	-₹871.22 Cr
Total Equity	-₹836.75 Cr
Long-Term Borrowings	₹0
Deferred Tax (Net)	—
Total Non-Current Liabilities	₹6.50 Cr
Short-Term Borrowings	₹0
Trade Payables	₹156.79 Cr
Total Current Liabilities	₹1404.97 Cr
Total Debt	₹0

Cash Flow Statement

Line Item	FY 2019
Operating Cash Flow	₹122.97 Cr
Investing Cash Flow	₹8.17 L
Financing Cash Flow	-₹123.45 Cr
Net Change in Cash	-₹39.06 L
Closing Cash Balance	₹2.57 Cr

Line Item	FY 2018	FY 2017	FY 2016	FY 2015
Net Revenue	₹148.64 Cr	₹183.27 Cr	₹254.32 Cr	₹314.66 Cr
Total Operating Cost	₹103.63 Cr	₹65.35 Cr	₹100.13 Cr	₹76.75 Cr
Operating Profit / (Loss)	-₹107.42 Cr	-₹20.04 Cr	-₹55.82 Cr	₹19.30 Cr
Other Income	₹13.23 L	₹41.70 L	₹4.34 Cr	₹5.85 Cr
Depreciation	₹32.63 Cr	₹32.79 Cr	₹32.64 Cr	₹30.42 Cr
Profit Before Tax	-₹323.64 Cr	-₹395.36 Cr	-₹180.85 Cr	-₹84.72 Cr
Income Tax	₹16.21 L	₹0	₹0	₹0
Profit After Tax (PAT)	-₹323.80 Cr	-₹395.36 Cr	-₹180.85 Cr	-₹84.72 Cr

🔒

5-Year Financial History

EV / EBITDA Multiple

-2.82x

MCAP:
₹123.00 Cr

EBITDA:
₹-42.71 Cr

OCF vs PAT Ratio

Revenue & Profit Trend

Key Ratios

🔒

Key Ratios Chart

Debt & Equity

Cash Flow Breakdown

Key Ratios Table

Ratio	FY 2019
Return on Equity	—
Return on Capital Employed	—
Current Ratio	0.03x
Quick Ratio	0.01x
Debt / Equity	0.00x
Interest Coverage	-0.60x
Net Margin	-190.65%
EBITDA Margin	-41.18%
Revenue Growth	-30.22%

🔒

Key Ratios Table

IPO Readiness Scorecard

60/ 100

Compliance Status0/25

Inactive/Warn

Financial Scale25/25

> ₹10Cr Revenue

Legal & Defaults10/25

Flags Detected

Governance & Cap25/25

Stable

Compliance Dashboard

Bureau Defaults

✗ Reported

Legal Cases (Pending)

✗ Cases Pending

GST Filing Status

✗ Delays Observed

EPF Payment Status

✗ Delays Observed

MCA Compliance

✓ INACTIVE

MSME Payment Delays

✓ None Detected

Insolvency / BIFR History

✓ No History

Auditor Stability (YoY)

✗ Auditor Changed

Related Party Transactions

Loans to/from Related Entities

Extracted from AOC-4 disclosures. Currently within normal safe limits.

Remuneration vs Profits

Management remuneration ratio stable against net profit bounds.

Credit Ratings

ℹ No recent credit ratings on file.

Legal Case Timeline

🔒

Governance & Compliance

Shareholding Summary (2018)

Total Equity Shares3,44,68,417

Promoter Holders2

Preference Shares0

Public / Other Holders46

Shareholding Pattern

100%

Equity

Promoter51%

Public / Others49%

Major Shareholders (>5%)

👤

MEHUL JAYANT PAREKH

IndividualDirector

54,14,350

% Holding

15.71%

Category-wise Shareholding Breakdown

Shareholder Type	Category	Indian Held (Shares)	Body Corporate (Shares)	Total Shares	% Holding
PROMOTER	equity	62,31,550	0	62,31,550	18.08%
PROMOTER	preference	0	0	0	0%
PUBLIC	equity	26,67,862	79,88,009	2,82,36,867	81.92%
PUBLIC	preference	0	0	0	0%

Corporate Group Structure

Holding Companies

No holding companies mapped.

Subsidiaries

No subsidiaries mapped.

Charges & Liens Detail

Tax & Employee Registrations

GST: Information Gated

EPFO: Information Gated

🔒

Cap Table & Shareholding

Industry: Pharma — API Manufacturers

Sample Size: 30 peers (2019 data)

Target Company Ratios vs Industry Median

Parameter	Company Value	Industry Median	Status
Revenue (₹ Cr)	103.71	103.49	▲
Revenue Growth (%)	-30.22	20.79	▼
EBITDA Margin (%)	-41.18	11.03	▼
Net Margin (%)	-190.65	5.66	▼
Return on Equity (%)	N/A	21.81	—
Debt / Equity	0	0.56	▲
Inventory / Sales (Days)	82.30	60.35	▼
Debtors / Sales (Days)	51.73	98.53	▲
Payables / Sales (Days)	551.79	69.52	▲
Cash Conversion Cycle (Days)	-417.76	90.20	▲
Sales / Net Fixed Assets	0.34	5.12	▼

Closest Peers by Revenue

Company Name	CIN	City	Revenue (₹)
ATUL BIOSCIENCE LIMITED	U24230GJ1997PLC032369	VALSAD	1,05,10,44,000
M. J. BIOPHARM PRIVATE LIMITED	U24234PN2002PTC158855	PUNE	1,05,04,54,802
UNIMARK REMEDIES LIMITED	U23200MH1993PLC075373	Mumbai	1,03,71,15,220
CHANDAK LABORATORIES PRIVATE LIMITED	U24230TG1985PTC005415	HYDERABAD	1,03,26,22,523
MAC-CHEM PRODUCTS (INDIA) PRIVATE LIMITED	U24239MH1991PTC062948	MUMBAI	1,03,08,48,492

Recent News

No recent news found or analyzed for this company.

Latest Filings

📄

AOC-4 (Annual Financials)

FY 2023-24 | Filed on: 13 Feb 2025

📄

MGT-7 (Annual Return)

FY 2022-23 | Filed on: 20 Feb 2024

📅

Last AGM Date

30 Sep 2024

SWOT Analysis

+ Strengths

Established company incorporated in 1993, indicating longevity in the market.
Focuses on manufacturing and marketing Active Pharmaceutical Ingredients (APIs), intermediates, and fine chemicals, a critical segment of the pharma industry.
Structured approach to product lifecycle management (commercialized, pipeline, R&D APIs) suggests commitment to innovation and market expansion.
Robust international presence, supplying to over 35 countries globally, including major pharmaceutical players, indicating adherence to international quality standards and competitive positioning.

− Weaknesses

Significant financial loss with a PAT of ₹-197.72 Cr and a Net Margin of -190.7% as of 2019-03-31.
Classified as 'Loss Making' in the profit band.
Bureau Defaults are present.
Pending Cases are present.
GST Delay is present.
EPF Delay is present.
Relatively small employee count (Upto 100) for a company with international operations.

💡 Opportunities

Continued demand for APIs globally, positioning the company as a key supplier for pharmaceutical formulations.
Expansion of product categories through ongoing R&D and pipeline development.
Leveraging existing international network in over 35 countries to further penetrate global markets.

⚠️ Threats

Significant financial losses and negative net margin pose a severe threat to long-term viability.
Bureau Defaults, Pending Cases, GST Delay, and EPF Delay indicate potential operational and regulatory compliance risks.
Intense competition within the global API market from other established players.
Potential for further financial deterioration if losses continue.

AI Generated FAQs

No standard FAQs automatically synthesized yet.

🔒

Documents & Filings

UNIMARK REMEDIES LIMITED

Company Summary

🎙️ Company Audio Brief

💡 Quick Investor Summary

Key Highlights

Management Team

IPO Tracker

Financial Statements

Profit & Loss Statement

Balance Sheet

Cash Flow Statement

Charts & Ratios

OCF vs PAT Ratio

Revenue & Profit Trend

Key Ratios

Debt & Equity

Cash Flow Breakdown

Key Ratios Table

Governance & Compliance

Capitalization Table

Peer Comparison

Target Company Ratios vs Industry Median

Closest Peers by Revenue

Latest News

Recent News

Documents & Filings